Open Access Open Access  Restricted Access Subscription or Fee Access

Laboratory-based testing to evaluate abuse-deterrent formulations and satisfy the Food and Drug Administration's recommendation for Category 1 Testing

Christopher Altomare, BS, Eric R. Kinzler, PhD, August R. Buchhalter, PhD, Edward J. Cone, PhD, Anthony Costantino, PhD

Abstract


The US Food and Drug Administration (FDA) considers the development of abuse-deterrent formulations of solid oral dosage forms a public health priority and has outlined a series of premarket studies that should be performed prior to submitting an application to the Agency. Category 1 studies are performed to characterize whether the abuse-deterrent properties of a new formulation can be easily defeated. Study protocols are designed to evaluate common abuse patterns of prescription medications as well as more advanced methods that have been reported on drug abuse websites and forums. Because FDA believes Category 1 testing should fully characterize the abuse-deterrent characteristics of an investigational formulation, Category 1 testing is time consuming and requires specialized laboratory resources as well as advanced knowledge of prescription medication abuse. Recent Advisory Committee meetings at FDA have shown that Category 1 tests play a critical role in FDA's evaluation of an investigational formulation. In this article, we will provide a general overview of the methods of manipulation and routes of administration commonly utilized by prescription drug abusers, how those methods and routes are evaluated in a laboratory setting, and discuss data intake, analysis, and reporting to satisfy FDA's Category 1 testing requirements.


Keywords


category 1 testing, abuse deterrent, formulation, laboratory-based testing, pharmaceutical, tamper resistant

Full Text:

PDF

References


Centers for Disease Control and Prevention: Policy Impact: Prescription Painkiller Overdoses. 2011.

Substance Abuse and Mental Health Services Administration: Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-41, HHS Publication No. (SMA) 11-4658. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2011.

US Food and Drug Administration: FDA issues draft guidance on abuse-deterrent opioids. 2013.

Katz N: Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep. 2008; 10: 11-8.

Lankenau SE, Teti M, Silva K, et al.: Initiation into prescription opioid misuse amongst young injection drug users. Int J Drug Policy. 2012; 23: 37-44.

Budman SH, Grimes Serrano JM, Butler SF: Can abuse deterrent formulations make a difference? Expectation and speculation. Harm Reduction J. 2009; 6: 8.

Katz N, Dart RC, Bailey E, et al.: Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse. 2011; 37: 205-217.

Hale ME, Moe D, Bond M, et al.: Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain. Pain Manag. 2016; 6: 497-508.

Green JL, Bucher Bartelson B, Le Lait MC, et al.: Medical outcomes associated with prescription opioid abuse via oral and nonoral routes of administration. Drug Alcohol Depend. 2017; 175: 140-145.

US Food and Drug Administration: Regulatory History of Opana ER. 2017.

US Food and Drug Administration: Abuse-Deterrent Opioids-Evaluation and Labeling. 2015.

US Food and Drug Administration: DRAFT GUIDANCE-General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products. 2016.

Takaki P, Vieira M, Bommarito S: Maximum bite force analysis in different age groups. Int Arch Otorhinolaryngol. 2014; 18: 272-6.

Gasior M, Bond M, Malamut R: Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations. Postgrad Med. 2016; 128: 85-96.




DOI: http://dx.doi.org/10.5055/jom.2017.0420

Refbacks

  • There are currently no refbacks.